

#### **Committee Name**

Thoracic Oncology Group of Australasia (TOGA) Consumer Panel, hereafter referred to as 'CP'.

#### **Foreword**

TOGA recognises the value of consumers, patients, and caregivers being involved in all aspects of research that relates to them, including research priority setting.

#### **Purpose**

The primary purpose of the CP is to bring together TOGA community members involved in research or in review of material for research studies that are provided to patients.

TOGA Consumer involvement in research operates according to the TOGA Position Statement "Consumer and Community Involvement in Thoracic Cancer Research", and subsequent amendments.

Members of the CP may also choose to become involved in other activities including, but not limited to, membership of TOGA Committees and/or Working Groups, involvement in fundraising initiatives or review of awards.

#### Joining the Consumer Panel

The process to join the Consumer Panel is as follows:

Candidate nominates interest area as 'Contribution to research activities' in community membership application, or responds to expression of interest for involvement in research.

An informal discussion between the candidate and TOGA CEO, and optional attendance by an experienced consumer representative, to ensure there is alignment in the expectations and activities of consumer involvement.

If a consumer representative joined the informal discussion, the TOGA CEO and consumer representative will discuss whether an invitation should be extended.

TOGA CEO invites new consumer representative to join the CP.

#### **Essential criteria**

The essential criterion for a member of the CP is their commitment to clinical trials as a key strategy for improving the outcomes of those affected by cancer. This includes supporting and promoting every person's right to information concerning trials and their right to make a personal, informed choice. As consumer advisers they are not asked to provide, nor expected to have, specific expertise about the scientific or medical merits of a trial. CP members are asked to provide the perspective of someone who has been through a similar or related experience.

Members of the CP must be members of TOGA.

#### Induction

All members of the CP will be asked to undergo/undertake any training that is designed to inform and assist members on how to better perform their role as a member of the CP.



Initial suggested training is the Cancer Australia training for consumer involvement in the cancer cooperative clinical trial groups and consumer involvement training provided by Telethon Kids.

https://consumerlearning.canceraustralia.gov.au/

https://training.telethonkids.org.au/courses/consumer-introduction/

New CP members will be provided an Orientation Pack, which includes:

- CP Terms of Reference
- TOGA Code of Conduct
- · CP member contact details
- Relevant TOGA operational and personnel information
- · List of TOGA clinical Trials
- · List of commonly used abbreviations
- Any other pertinent information

Every effort will be made to assign new CP members to an experienced CP member 'buddy' who can provide mentorship and guidance during the initial involvement activities.

#### Review of clinical trial concepts

For involvement in very early concept design and review and recommendations for TOGA endorsement, consumer representatives should join TOGA working groups <a href="https://thoraciconcology.org.au/working-group/">https://thoraciconcology.org.au/working-group/</a>.

Once concepts reach a more mature stage (eg protocol), members of the CP will be invited to provide feedback on a research design during a meeting with the lead investigator. Prior to the meeting, the written concept will be circulated as pre-reading. It is estimated that these opportunities arise approximately once/year.

The TOGA study chair or lead researcher will be expected to present a verbal outline of the clinical trial concept at the meeting and be available to answer questions on the research. The consumer representatives may choose to conduct further discussion on the concept without the study chair present and submit written feedback or may choose for the study chair to remain for the discussion and receive direct communication regarding the consumer views.

#### Involvement in research projects and grant applications

Periodically, TOGA receives requests from researchers to identify consumer representatives who are willing to be involved in research projects or grant applications. These may or may not be TOGA-endorsed projects, but it is important to note that TOGA has no ability to define consumer involvement for these research projects. These opportunities will be circulated to the Consumer Panel, and interested consumer representatives asked to express interest to the researcher directly.

Consumer representatives who attend working group meetings should identify themselves to researchers independently if they wish to be involved in a particular project.

#### **Communication of Consumer Priorities**

In recognition of the importance of communicating consumer priorities, prior to design of research, the TOGA Consumer Panel will meet annually with the TOGA Working group co-chair, Scientific Committee chair and other interested members of the SC to outline their priorities and receive



feedback. Ideally, this will result in jointly agreed priorities for design of research concepts. A standing item will be included on the SC agenda to address these priorities.

#### **Expectations of members and TOGA**

CP members are expected to treat others in a way that is polite, respectful, transparent, and culturally sensitive.

TOGA respects and understands that CP members are volunteers, many with personal, professional and/or family commitments. TOGA appreciates that participation in CP is voluntary, and recognises that from time to time, CP members' personal circumstances may prevent them from taking on additional duties or active participation in assigned roles. TOGA understands that this does not indicate a lack of interest in TOGA's activities or in continuing a role on CP.

#### Chairperson

Following an Expression of Interest process within the CP members, the Chairperson of the CP/Executive Committee shall be appointed by the Board. The Chairperson shall chair all meetings.

The Chairperson shall be appointed for two years. A retiring Chairperson may be re-appointed for a subsequent two-year term, following an Expression of Interest process.

The Committee may appoint from its membership a person to deputise for the Chairperson in his/her absence.

The Chairperson shall design the agenda with the CEO.

The Chairperson shall work with the CEO to ensure updates are given to each SC meeting, and to organise an annual meeting with the Working Groups co-chairs.

#### **Meetings**

The CP will meet as required by videoconference approximately two times/year.

An agenda for the meeting will be prepared by the Chair and TOGA CEO, following a call for items approximately 21 days in advance of the meeting. Items not advised in advance will not be discussed at the meeting. The agenda will include, but is not limited to:

- · Declaration of conflicts of interest
- Acceptance of previous meeting minutes
- Welcome to new members
- Lessons learned and consumer involvement experiences
- Training requirements
- An update on the TOGA clinical trial program
- Dates of next meetings
- Other business

In general, the CP will adopt a consensus approach when establishing recommendations, where a majority of members agree, with the remainder content to give way. Any objections will be noted in the minutes. If a decision does require voting, and the vote is tied, the Chair will have the casting vote.



#### Reporting

TOGA will evaluate and report on consumer and community involvement in research involvement alongside other academic metrics of success.

#### **Budget and expenses**

The cost of administration for the CP will be managed by the TOGA CEO.

#### Confidentiality and conflict of interest

CP members will complete the Conflict of Interest Declaration annually and update as needed. Members with a conflict of interest to declare in relation to new topics will make a declaration prior to the discussion.

CP members are required to keep all matters confidential unless disclosure of matters discussed is required for the effective oversight of the activity. The TOGA Confidentiality Statement will be signed by each member upon appointment to the CP.

#### **Grievance procedure**

Complaints in relation to the activities and operation of the CP should be made in writing to the TOGA CEO. The complaint will be considered by three TOGA members free of conflicts, nominated by the TOGA CEO/TOGA Chair. The decision whether to table the complaint at a CP meeting will be at the discretion of these three nominated members who consider the complaint. Regardless of whether the complaint is tabled at a meeting or resolved out of meeting, the complaint and the outcome of the deliberations should be minuted and communicated to the complainant by letter. The resolution of the complaint should also be recorded in the minutes.

CP members should not contact the Chair of TOGA directly. In the instance where the TOGA CEO is considered to be in conflict, the complaint can be sent to info@thoraciconcology.org.au

#### References

National Framework for Consumer Involvement in Cancer Control. Cancer Australia and Cancer Voices Australia (2011). Cancer Australia, Canberra, ACT.

Committee Terms of Reference. Guidance for CTNs, May 2019. Australian Clinical Trials Alliance (2019) Melbourne, VIC.

Statement on Consumer and Community involvement in Health and Medical Research, National Health and Medical Research Council (2016), Consumers Health Forum of Australia.

TOGA Position Statement "Consumer and Community Involvement in Thoracic Cancer Research"

#### Review and approval

The Terms of Reference for the Consumer Panel shall be reviewed by the committee and approved by the Thoracic Oncology Group of Australasia Board every 3 years.

Name of the document	TOGA CP Terms of Reference	
Version	4	



Replaces	Version 3.0, June 2024		
Reviewed by and date	TOGA Board of Directors, May 2024		
Approved by and date	TOGA Board of Directors, May 2024		
Next review date	September 2027		



#### APPENDIX 1 Expression of interest form

TOGA Consumer Panel (CP) has been established to provide a structure for consumer representatives and TOGA Community Members to be involved in research.

This application form will help provide us with information about you that will help TOGA ensure your interests and those of TOGA are aligned.

Pending mutual agreement regarding your involvement, we will invite you to join TOGA and formally become a member of the CP. The CP meets approx. twice per year to welcome new members, to share experiences and learnings from involvement in research and to discuss any training or mentoring needs.

Invitations to review research will be sent out by email with interested consumers/community members to self-nominate. As a guide to time commitment, each concept takes around 3 hours, each consent form around 2 hours, each lay summary around 1 hour, and a grant application 1-2 days. Not all members need to review every item, but as a guide, you would be expected to review around 3 items per year.

Thank you for your interest in joining the TOGA Consumer Panel. Please fill in this application form and send it to TOGA at info@thoraciconcology.org.au

To discuss this in any way and for more information please contact:

Megan Sanders

**TOGA CEO** 

megan.sanders@thoraciconcology.org.au

Thank you for your interest in joining TOGA.

Yours sincerely

Megan Sanders



Applicant	details
Surname	Given Name
Email	
Address	
Phone	
Lung canc	er/Mesothelioma ('Thoracic cancer') Connection:
	I have or had lung cancer/mesothelioma
	My family member has or had lung cancer/mesothelioma
	My family member died of lung cancer/mesothelioma
Time since	e diagnosis
	<1 year   8-10 years
	2-4 years $\Box$ 11+ years
	5-7 years
	experience
	nat is your experience in consumer advocacy or representation?
	Sharing your personal story publicly
	Working with researchers
	Working with research funders (e.g. grant reviews)
	Working with healthcare providers (e.g. hospitals)
	Fundraising for lung cancer research or advocacy organisations
	Attending lung cancer scientific meetings or conferences
	Organising educational events for the community
	Actively participating in online lung cancer communities
	Other:
2. Are	e you prepared to liaise with thoracic cancer clinicians and researchers?   Yes
	No
0 4	
	e you prepared to attend meetings remotely (by phone or virtual/online)?
	No
4. Ple	ease provide your social media
lini	ks: • Blog/website:
	• Twitter: • Other:
	<ul> <li>Facebook:</li> <li>□ Not on social media</li> </ul>
	Instagram:
Applicant	
_	w did you find out about the TOGA Consumer Panel?
	Word of mouth
	TOGA's website
	Clinician or medical team
	Another organisation:
	Other:
6. Wh	ny are you expressing interest in joining the TOGA Consumer Panel?



7. The TOGA working groups are the structure for review and input into early design of concepts. Please indicate the working groups you would like to join.				
□ SCLC/Mesothe □ Advanced NSC	e research c lioma resear LC research	rking Group oncept development working group ch concept development working group concept development working group IB) research concept development working group		
Please email if you would like	more detail	on these areas.		
Declaration				
By signing this form:				
I authorise the Thoracic Oncology Group of Australasia Ltd ('TOGA') to collect my personal information and handle them in accordance with the <i>Privacy Act 1988</i> (Cth) and the TOGA Privacy Policy. More information about how information is handled by TOGA can be found in our privacy policy (available at <a href="https://thoraciconcology.org.au/terms-conditions-privacy-policy/">https://thoraciconcology.org.au/terms-conditions-privacy-policy/</a> ).  I wish to join the TOGA Consumer Panel, and I declare that to the best of my knowledge the information supplied within this application and any supporting document is correct.				
Signature				
Name				
Date				
Office use				
Notes				
Applicant is member of TOGA	Y/N	Date joined:		
Progress invitation to CP	Y/N	Reason if No		



#### APPENDIX 2 Confidentiality agreement

(1) I,	(name),
	(position) of,
	(organisation)
	(address),
acknowledge the confidential nature of all whether by verbal, written or electronic me	activities of the TOGA CP, including all discussions, eans and all associated documents.
• • •	or copies of documents to any third party outside the CP erms of Reference or agreed to in writing by the CP
(3) I understand that my obligations under am no longer a member of the CP.	this agreement continue to have full force and effect when I
Signature	Date://
SIGNED on behalf of TOGA by	
Position:	
Signature	Date://



### APPENDIX 3 POSITION DESCRIPTION OF TOGA CONSUMER REPRESENTATIVE

#### **DUTIES:**

- To provide feedback on research proposals and clinical trial documentation provided to consumers utilising lived experience of thoracic cancer.
- To undertake all background reading
- To be conscious of issues of diversity and representation and actively consider broader views –
  understanding and being conscious of the nature and limits of your specific personal experience
  and point of view and to consider a diversity of consumer needs and interests beyond these limits
- Familiarity with TOGA's Vision, Mission and Strategic Plan
- Adhere to TOGA Code of Conduct
- Attendance at training or seminars and/or participation in other development activities is strongly encouraged to support full and active participation in this role

#### **EXPERIENCE:**

- A personal experience of cancer as a patient, a person who has cared for another with cancer, or a family member or friend
- Membership of other consumer groups that enables a diverse and representative view to be brought to the review of research
- Written and verbal communication skills

#### **CONFIDENTIALITY AGREEMENT:**

Written declarations of confidentiality will be completed on appointment to the CP.

#### CONFLICT OF INTEREST:

Written declarations of interest/s that may give rise to a conflict will be submitted annually as per TOGA's policy. This is affirmed at every meeting, as well as an opportunity to declare any new interests that may give rise to a conflict.